Role of senescence and mitotic catastrophe in cancer therapy
<p>Abstract</p> <p>Senescence and mitotic catastrophe (MC) are two distinct crucial non-apoptotic mechanisms, often triggered in cancer cells and tissues in response to anti-cancer drugs. Chemotherapeuticals and myriad other factors induce cell eradication via these routes. While s...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-01-01
|
| Series: | Cell Division |
| Online Access: | http://www.celldiv.com/content/5/1/4 |
| _version_ | 1819029336014979072 |
|---|---|
| author | Shukla Yogeshwer George Jasmine Singh Richa |
| author_facet | Shukla Yogeshwer George Jasmine Singh Richa |
| author_sort | Shukla Yogeshwer |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Senescence and mitotic catastrophe (MC) are two distinct crucial non-apoptotic mechanisms, often triggered in cancer cells and tissues in response to anti-cancer drugs. Chemotherapeuticals and myriad other factors induce cell eradication via these routes. While senescence drives the cells to a state of quiescence, MC drives the cells towards death during the course of mitosis. The senescent phenotype distinguishes tumor cells that survived drug exposure but lost the ability to form colonies from those that recover and proliferate after treatment. Although senescent cells do not proliferate, they are metabolically active and may secrete proteins with potential tumor-promoting activities. The other anti-proliferative response of tumor cells is MC that is a form of cell death that results from abnormal mitosis and leads to the formation of interphase cells with multiple micronuclei. Different classes of cytotoxic agents induce MC, but the pathways of abnormal mitosis differ depending on the nature of the inducer and the status of cell-cycle checkpoints. In this review, we compare the two pathways and mention that they are activated to curb the growth of tumors. Altogether, we have highlighted the possibilities of the use of senescence targeting drugs, mitotic kinases and anti-mitotic agents in fabricating novel strategies in cancer control.</p> |
| first_indexed | 2024-12-21T06:12:38Z |
| format | Article |
| id | doaj.art-1f8e0c8e16214954898b5eaa75ea4e5b |
| institution | Directory Open Access Journal |
| issn | 1747-1028 |
| language | English |
| last_indexed | 2024-12-21T06:12:38Z |
| publishDate | 2010-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Cell Division |
| spelling | doaj.art-1f8e0c8e16214954898b5eaa75ea4e5b2022-12-21T19:13:29ZengBMCCell Division1747-10282010-01-0151410.1186/1747-1028-5-4Role of senescence and mitotic catastrophe in cancer therapyShukla YogeshwerGeorge JasmineSingh Richa<p>Abstract</p> <p>Senescence and mitotic catastrophe (MC) are two distinct crucial non-apoptotic mechanisms, often triggered in cancer cells and tissues in response to anti-cancer drugs. Chemotherapeuticals and myriad other factors induce cell eradication via these routes. While senescence drives the cells to a state of quiescence, MC drives the cells towards death during the course of mitosis. The senescent phenotype distinguishes tumor cells that survived drug exposure but lost the ability to form colonies from those that recover and proliferate after treatment. Although senescent cells do not proliferate, they are metabolically active and may secrete proteins with potential tumor-promoting activities. The other anti-proliferative response of tumor cells is MC that is a form of cell death that results from abnormal mitosis and leads to the formation of interphase cells with multiple micronuclei. Different classes of cytotoxic agents induce MC, but the pathways of abnormal mitosis differ depending on the nature of the inducer and the status of cell-cycle checkpoints. In this review, we compare the two pathways and mention that they are activated to curb the growth of tumors. Altogether, we have highlighted the possibilities of the use of senescence targeting drugs, mitotic kinases and anti-mitotic agents in fabricating novel strategies in cancer control.</p>http://www.celldiv.com/content/5/1/4 |
| spellingShingle | Shukla Yogeshwer George Jasmine Singh Richa Role of senescence and mitotic catastrophe in cancer therapy Cell Division |
| title | Role of senescence and mitotic catastrophe in cancer therapy |
| title_full | Role of senescence and mitotic catastrophe in cancer therapy |
| title_fullStr | Role of senescence and mitotic catastrophe in cancer therapy |
| title_full_unstemmed | Role of senescence and mitotic catastrophe in cancer therapy |
| title_short | Role of senescence and mitotic catastrophe in cancer therapy |
| title_sort | role of senescence and mitotic catastrophe in cancer therapy |
| url | http://www.celldiv.com/content/5/1/4 |
| work_keys_str_mv | AT shuklayogeshwer roleofsenescenceandmitoticcatastropheincancertherapy AT georgejasmine roleofsenescenceandmitoticcatastropheincancertherapy AT singhricha roleofsenescenceandmitoticcatastropheincancertherapy |